"Infliximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chimeric monoclonal antibody to TNF ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE.
| Descriptor ID |
D000069285
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.608 D12.776.124.790.651.114.224.537 D12.776.377.715.548.114.224.642
|
| Concept/Terms |
Infliximab- Infliximab
- MAb cA2
- Monoclonal Antibody cA2
- cA2, Monoclonal Antibody
|
Below are MeSH descriptors whose meaning is more general than "Infliximab".
Below are MeSH descriptors whose meaning is more specific than "Infliximab".
This graph shows the total number of publications written about "Infliximab" by people in this website by year, and whether "Infliximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 3 | 3 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 38 | 26 | 64 |
| 2018 | 36 | 31 | 67 |
| 2019 | 8 | 14 | 22 |
| 2020 | 3 | 3 | 6 |
| 2021 | 6 | 2 | 8 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Infliximab" by people in Profiles.
-
Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for Therapeutic Drug Monitoring in patients with Inflammatory Bowel Disease. J Crohns Colitis. 2022 Feb 23; 16(2):190-198.
-
Infliximab Precipitated Urachal Remnant Infection. J Clin Rheumatol. 2021 Sep 01; 27(6):e219-e221.
-
Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies. Dermatol Ther. 2021 Sep; 34(5):e15088.
-
WHO relaunches global drug trial with three new candidates. Science. 2021 08 06; 373(6555):606-607.
-
Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD. Nat Rev Gastroenterol Hepatol. 2021 05; 18(5):286.
-
Safety of Biological Therapy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2021 05 01; 72(5):736-741.
-
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 10; 70(10):1884-1893.
-
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease. J Crohns Colitis. 2021 Apr 06; 15(4):687-691.
-
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021 05; 70(5):865-875.
-
Impact of Treatment With TNF-a Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic. J Cutan Med Surg. 2021 Jul-Aug; 25(4):446-448.